Disease · MONDO_0019080

alopecia totalis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. alopecia totalis. Diseases, record MONDO_0019080. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019080

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: alopecia totalis; Open Targets
Open Targets ID: MONDO_0019080; Open Targets
Orphanet: ORPHA:700; Orphanet
Highest stage of its drugs: Phase 3, for 1 of its 15 drugs, from ClinicalTrials.gov; Open Targets

Drugs15

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TOFACITINIB	CHEMBL221959	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
BOTULINUM TOXIN TYPE A	CHEMBL4297862	Protein	Phase 2/3	ClinicalTrials.gov	1	1	0	Drugs and targets
LETIBOTULINUMTOXINA	CHEMBL3707322		Phase 2/3	ClinicalTrials.gov	1	1	0	Drugs and targets
ONABOTULINUMTOXINA	CHEMBL1201574		Phase 2/3	ClinicalTrials.gov	1	1	0	Drugs and targets
IFIDANCITINIB	CHEMBL4594441	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
ABATACEPT	CHEMBL1201823	Protein	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
AZATHIOPRINE	CHEMBL1542	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
BETAMETHASONE	CHEMBL632	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
EFALIZUMAB	CHEMBL1201575	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
MINOXIDIL	CHEMBL802	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 15

See all 15 drugs

Targets89

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SNAP25	Synaptosomal-associated protein 25	3	Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor	Phase 2/3	https://conductscience.org/library/genes/6616	Drugs and targets
JAK1	Janus Kinase (JAK)	2	Janus Kinase (JAK) inhibitor	Phase 3	https://conductscience.org/library/genes/3716	Drugs and targets
JAK2	Janus Kinase (JAK)	2	Janus Kinase (JAK) inhibitor	Phase 3	https://conductscience.org/library/genes/3717	Drugs and targets
JAK3	Janus Kinase (JAK)	2	Janus Kinase (JAK) inhibitor	Phase 3	https://conductscience.org/library/genes/3718	Drugs and targets
NR3C1	Glucocorticoid receptor	2	Glucocorticoid receptor agonist	Phase 2	https://conductscience.org/library/genes/2908	Drugs and targets
PDE4A	3',5'-cyclic phosphodiesterase	2	3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 4 inhibitor	Phase 1	https://conductscience.org/library/genes/5141	Drugs and targets
PDE4B	3',5'-cyclic phosphodiesterase	2	3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 4 inhibitor	Phase 1	https://conductscience.org/library/genes/5142	Drugs and targets
PDE4C	3',5'-cyclic phosphodiesterase	2	3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 4 inhibitor	Phase 1	https://conductscience.org/library/genes/5143	Drugs and targets
PDE4D	3',5'-cyclic phosphodiesterase	2	3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 4 inhibitor	Phase 1	https://conductscience.org/library/genes/5144	Drugs and targets
TYK2	Janus Kinase (JAK)	2	Janus Kinase (JAK) inhibitor	Phase 3	https://conductscience.org/library/genes/7297	Drugs and targets

1 to 10 of 89

See all 89 targets

Trials15

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03759340	ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)	Phase 2	56	2020-09-17	Alopecia Areata, Alopecia Universalis, Alopecia Totalis	IFIDANCITINIB	Its record names the disease	ClinicalTrials.gov
NCT02312882	Tofacitinib for the Treatment of Alopecia Areata and Its Variants	Not applicable	40	2017-11-06	Alopecia Areata, Alopecia Totalis, Alopecia Universalis	TOFACITINIB	Its record names the disease	ClinicalTrials.gov
NCT02197455	Tofacitnib for the Treatment of Alopecia Areata and Variants	Phase 2	30	2017-04-04	Alopecia Areata (AA), Alopecia Totalis (AT), Alopecia Universalis (AU)	TOFACITINIB, TOFACITINIB CITRATE	Its record names the disease	ClinicalTrials.gov
NCT02684123	Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata	Not applicable	30	2023-11-07	Alopecia Areata	APREMILAST	Its record names the disease	ClinicalTrials.gov
NCT02018042	An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata	Phase 2	15	2019-04-17	Alopecia Areata	ABATACEPT	Its record names the disease	ClinicalTrials.gov
NCT02299297	Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis	Phase 2	12	2019-05-07	Alopecia Areata	TOFACITINIB	Its record names the disease	ClinicalTrials.gov
NCT03315689	Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)	Phase 2	11	2020-07-02	Alopecia Universalis (AU), Alopecia Totalis (AT)	IFIDANCITINIB	Its record names the disease	ClinicalTrials.gov
NCT02812342	Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants	Phase 2	10	2018-10-10	Alopecia Areata, Alopecia Totalis, Alopecia Universalis	TOFACITINIB	Its record names the disease	ClinicalTrials.gov
NCT03551821	Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata	Phase 2	1	2019-12-11	Alopecia Areata, Alopecia Totalis, Alopecia Universalis	IFIDANCITINIB	Its record names the disease	ClinicalTrials.gov
NCT06087796	Topical Pentoxifylline; Metformin Versus Betamethasone in the Treatment of Alopecia Areata.	Phase 1	60		Alopecia Areata	BETAMETHASONE VALERATE, METFORMIN, PENTOXIFYLLINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 15

See all 15 trials

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Apremilast vs Placebo: deaths from any cause	0 of 20	0 of 10	30	NCT02684123	Trial comparisons
Apremilast vs Placebo: serious adverse events	0 of 20	0 of 10	30	NCT02684123	Trial comparisons
Apremilast vs Placebo: Number of Patients With SALT50	1 of 1	1 of 9	10	NCT02684123	Trial comparisons

Papers from its trials18

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37955531	RESULT	1	PubMed
37521227	RESULT	1	PubMed
37339501	RESULT	1	PubMed
36177791	RESULT	1	PubMed
34211288	RESULT	1	PubMed
31799258	RESULT	1	PubMed
30302901	RESULT	1	PubMed
29273099	RESULT	1	PubMed
28300084	RESULT	1	PubMed
28139263	RESULT	1	PubMed

1 to 10 of 18

See all 18 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0019080

GET https://conductscience.org/api/diseases/v1/MONDO_0019080/targets?page=2

API reference For AI assistants